ALXO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ALX Oncology Holdings Inc (ALXO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators are neutral to slightly bearish, with no significant positive catalysts or strong trading signals. Additionally, the company's financial performance is weak, with declining net income and EPS. While there is a slight positive sentiment from analysts with an increased price target, the lack of significant growth or positive news makes this stock a hold for now.
The MACD is below 0 and negatively expanding, indicating bearish momentum. RSI is neutral at 50.317, suggesting no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock price is below the pivot level of 2.39, with resistance at 2.596 and support at 2.184. Overall, the technical indicators are mixed, leaning towards neutral to slightly bearish.
Analyst Piper Sandler raised the price target to $4 from $3 and maintained an Overweight rating, reflecting some optimism about the company's future prospects in breast cancer treatments.
No significant news or events in the past week. Financial performance is weak, with declining net income (-27.89% YoY) and EPS (-29.31% YoY). No recent trading activity from insiders, hedge funds, or Congress members.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped significantly to -$22.14M (-27.89% YoY), and EPS declined to -0.41 (-29.31% YoY). Gross margin remained at 0%. The financials indicate poor performance and no growth momentum.
Piper Sandler raised the price target to $4 from $3 and maintained an Overweight rating, reflecting some optimism. However, the updates are based on model adjustments rather than significant positive developments.
